What is the official website of Novartis Nederland - Cardiovascular, Renal & Metabolism ?

The official website of Novartis Nederland - Cardiovascular, Renal & Metabolism is https://www.zorgverlener.novartis.nl/therapeutische-gebieden/cardiologie.

What is Novartis Nederland - Cardiovascular, Renal & Metabolism's cybersecurity risk score?

Novartis Nederland - Cardiovascular, Renal & Metabolism has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Nederland - Cardiovascular, Renal & Metabolism experienced?

According to Rankiteo, Novartis Nederland - Cardiovascular, Renal & Metabolism currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Nederland - Cardiovascular, Renal & Metabolism been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Nederland - Cardiovascular, Renal & Metabolism has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Nederland - Cardiovascular, Renal & Metabolism have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Nederland - Cardiovascular, Renal & Metabolism does not hold a SOC 2 Type 2 certification.

Does Novartis Nederland - Cardiovascular, Renal & Metabolism have PCI DSS certification ?

According to Rankiteo, Novartis Nederland - Cardiovascular, Renal & Metabolism does not currently maintain PCI DSS compliance.

Does Novartis Nederland - Cardiovascular, Renal & Metabolism comply with HIPAA ?

According to Rankiteo, Novartis Nederland - Cardiovascular, Renal & Metabolism is not compliant with HIPAA regulations.

Does Novartis Nederland - Cardiovascular, Renal & Metabolism have ISO 27001 certification ?

According to Rankiteo,Novartis Nederland - Cardiovascular, Renal & Metabolism is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

How many employees does Novartis Nederland - Cardiovascular, Renal & Metabolism have ?

Novartis Nederland - Cardiovascular, Renal & Metabolism employs approximately None employees people worldwide.

Does Novartis Nederland - Cardiovascular, Renal & Metabolism own any subsidiaries ?

Novartis Nederland - Cardiovascular, Renal & Metabolism presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Nederland - Cardiovascular, Renal & Metabolism have ?

Novartis Nederland - Cardiovascular, Renal & Metabolism's official LinkedIn profile has approximately 570 followers.

What is the NAICS classification code for Novartis Nederland - Cardiovascular, Renal & Metabolism ?

Novartis Nederland - Cardiovascular, Renal & Metabolism is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Nederland - Cardiovascular, Renal & Metabolism have a Crunchbase profile ?

No, Novartis Nederland - Cardiovascular, Renal & Metabolism does not have a profile on Crunchbase.

Does Novartis Nederland - Cardiovascular, Renal & Metabolism have a LinkedIn profile ?

Yes, Novartis Nederland - Cardiovascular, Renal & Metabolism maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-pharma-nederland-cardiometabolic.

How many peer or competitor companies does Novartis Nederland - Cardiovascular, Renal & Metabolism have ?

Novartis Nederland - Cardiovascular, Renal & Metabolism has an estimated 5,706 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Nederland - Cardiovascular, Renal & Metabolism faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Cyber Attack and Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

NNCRM

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

Novartis Nederland - Cardiovascular, Renal & Metabolism Vendor Cyber Rating & Cyber Score

novartis.nl

Add Your Compliance Badge

Het cardiometabolic team van Novartis zet zich in voor onderzoek naar en ontwikkeling van nieuwe therapieën en oplossingen om de last van hart- en vaatziekten en metabole aandoeningen over de hele wereld te verminderen. Met deze inspanningen maken we ons hard om voor patiënten betere resultaten te bereiken. De richtlijnen van onze LinkedIn pagina kan je terugvinden op https://www.novartis.nl/sites/www.novartis.nl/files/linkedin-community-guidelines-NL.pdf

NNCRM A.I CyberSecurity Scoring

Scoring History

NNCRM

Novartis Nederland - Cardiovascular, Renal & Metabolism CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Nederland ...

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

NNCRM Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for NNCRM

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Nederland - Cardiovascular, Renal & Metabolism in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Nederland - Cardiovascular, Renal & Metabolism in 2026.

Incident Types NNCRM vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Nederland - Cardiovascular, Renal & Metabolism in 2026.

Incident History - NNCRM (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Nederland - Cardiovascular, Renal & Metabolism Subsidiaries

NNCRM

Pharmaceutical Manufacturing

Website: https://www.zorgverlener.novartis.nl/therapeutische-gebieden/cardiologie

Company Size: 10,001+ employees

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - NeurologiePharmaceutical Manufacturing

Novartis Nederland - HematologieGeneesmiddelenproductie

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis EuropePharmaceutical Manufacturing

Novartis MalaysiaPharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis Nederland - DermatologiePharmaceutical Manufacturing

Novartis Nederland - OncologiePharmaceutical Manufacturing

Loading…

Novartis Nederland - Cardiovascular, Renal & Metabolism Similar Companies

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

Loading…

NEWS

Novartis Nederland - Cardiovascular, Renal & Metabolism CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

November 25, 2025 08:00 AM

Novartis Canada Welcomes Dimitri Gitas as New Country President

MONTREAL, QC, November 25, 2025 – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is pleased to announce the appointment of Dimitri...

Read Article

November 04, 2025 08:00 AM

New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline

Fabhalta and Vanrafia Phase III analyses, Fabhalta real-world treatment pattern data, and zigakibart Phase I/II trial showcase strength of...

Read Article

October 16, 2025 07:00 AM

Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)

In APPLAUSE-IgAN final analysis, Fabhalta demonstrated statistically significant, clinically meaningful improvement in estimated glomerular...

Read Article

September 03, 2025 07:00 AM

Argo Biopharma Announces Multi-Asset License and Option Agreements with Novartis for Novel Molecules for Cardiovascular Diseases

PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma, the Company), a clinical-stage biotechnology company focused on developing...

Read Article

August 30, 2025 07:00 AM

Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

V-DIFFERENCE is first study to show that Leqvio prioritized after statins helps more patients achieve guideline low-density lipoprotein...

Read Article

August 18, 2025 05:33 AM

New Novartis ESC data highlights strength of cardiovascular portfolio

Two VictORION studies will highlight Leqvio's impact on patient quality of life, and as a cholesterol lowering monotherapy. Lp(a)FRONTIERS APHERESIS study...

Read Article

June 24, 2025 07:00 AM

3 Innovative Ways We’re Reaching Patients, Beyond Our Medicines

When it comes to addressing the biggest health challenges we face today – from cancer to heart disease -- science alone isn't enough.

Read Article

February 11, 2025 08:00 AM

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody...

Read Article

October 26, 2024 07:00 AM

Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial

New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-58281

SUMMARY

Deserialization of untrusted data in Microsoft Edge (Chromium-based) allows an unauthorized attacker to execute code over a network.

Published

Date2026-07-11

Updated

Date2026-07-11

RISK INFORMATION (Score: 8.3)

cvss3

Base Score: 8.3

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:R/S:C/C:H/I:H/A:H

Impact Score

Exploitability

1.6

REFERENCES

https://msrc.microsoft.com/update-guide/vulnerability/CVE-2026-58281

CVE-2026-10660

SUMMARY

The Bluetooth BAP Broadcast Assistant GATT client in subsys/bluetooth/audio/bap_broadcast_assistant.c reassembled remote Broadcast Receive State data into a single file-static net_buf_simple (att_buf, BT_ATT_MAX_ATTRIBUTE_LEN = 512 bytes) shared by all connection instances, while the BUSY flag, long-read handle, and reset/offset state were per-connection. When the device acts as a Broadcast Assistant connected to multiple Scan Delegator peripherals, notification and long-read callbacks from different connections interleave on the shared buffer: the append in notify_handler (net_buf_simple_add_mem at the not-busy branch) performs no tailroom check, so receive-state notifications from two or more delegators accumulate on the same 512-byte buffer and, with a sufficiently large configured ATT MTU (BT_L2CAP_TX_MTU up to 2000) and two-to-three concurrent connections, write past the buffer into adjacent .bss (net_buf_simple_add only asserts in debug builds). Even below the overflow threshold, one connection's net_buf_simple_reset zeroes the shared length while another connection's reassembly and GATT read offset are in flight, mixing one peer's data into another's parse. A malicious or compromised Scan Delegator (or two colluding peers) over BLE can trigger this, causing out-of-bounds writes (memory corruption / denial of service) and cross-connection data corruption. The fix moves the buffer into the per-connection instance struct so each connection reassembles into its own buffer. Affects Zephyr releases shipping the Broadcast Assistant with the shared buffer, including v4.4.0 and earlier.

Published

Date2026-07-11

Updated

Date2026-07-11

RISK INFORMATION (Score: 6.4)

cvss3

Base Score: 6.4

Complexity: HIGH

CVSS:3.1/AV:A/AC:H/PR:N/UI:N/S:U/C:L/I:L/A:H

Impact Score

4.7

Exploitability

1.6

REFERENCES

CVE-2026-61870

SUMMARY

ImageMagick before 7.1.2-26 contains a memory leak vulnerability in the VIFF encoder when memory allocation fails. Attackers can trigger allocation failures by processing specially crafted VIFF images to exhaust available memory and cause denial of service.

Published

Date2026-07-11

Updated

Date2026-07-11

RISK INFORMATION (Score: 2.9)

cvss3

Base Score: 2.9

Complexity: HIGH

CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L

cvss4

Base Score: 2.1

Complexity: HIGH

CVSS:4.0/AV:L/AC:H/AT:P/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

1.4

REFERENCES

CVE-2026-61861

SUMMARY

ImageMagick before 7.1.2-26 contains a use-after-free vulnerability in the FormatMagickCaption method when memory allocation fails. Attackers can trigger memory allocation failures to cause a dangling pointer to reference freed memory, potentially enabling denial of service or code execution.

Published

Date2026-07-11

Updated

Date2026-07-11

RISK INFORMATION (Score: 3.7)

cvss3

Base Score: 3.7

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L

cvss4

Base Score: 6.3

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.2

REFERENCES

CVE-2026-61858

SUMMARY

ImageMagick before 7.1.2-26 contains a policy bypass vulnerability in the APNG encoder and external delegates due to missing validation checks. Attackers can write files to disallowed paths by bypassing configured policy restrictions through the APNG encoding process.

Published

Date2026-07-11

Updated

Date2026-07-11

RISK INFORMATION (Score: 3.3)

cvss3

Base Score: 3.3

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:N

cvss4

Base Score: 4.8

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:L/UI:N/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

1.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…